NCT01880320View on ClinicalTrials.gov

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

PHASE3CompletedINTERVENTIONAL

Enrollment

503

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Acne Vulgaris

Interventions

DRUG

CD0271 0.3% / CD1579 2.5%

DRUG

CD0271 0.1% / CD1579 2.5%

DRUG

Topical Gel Vehicle

Trial Locations (31)

Unknown

Galderma Investigational site, Birmingham

Galderma Investigationnal Site, Mobile

Galderma investigational Site, Hot Springs

Galderma Investigational Site, Los Angeles

Galderma Investigational Site, Sacramento

Galderma Investigational Site, Santa Monica

Galderma Investigational Site, Miami

Galderma Investigational Site, Miramar

Galderma Investiogational Site, Newnan

Galderma Investigational Site, Snellville

Galderma Investigational Site, Chicago

Galderma Investigational Site, Detroit

Galderma Investigational Site, Albuquerque

Galderma Investigational Site, New York

Galderma Investigational Site, Stony Brook

Galderma Investigational Site, Raleigh

Galderma Investigational Site, Beachwood

Galderma investigational Site, Hershey

Galderma Investigational Site, Greenville

Galderma Investigational Site, Goodlettsville

Galderma Investigational Site, Knoxville

Galderma Investigational Site, Arlington

Galderma Investigational Site, San Antonio

Galderma Investigational Site, Salt Lake City

Galderma Investigational Site, Spokane

Galderma Investigational Site, Barrie

Galderma Investigational Site, Markham

Galderma Investiogational Site, Montreal

Galderma Investigational Site, Peterborough

Galderma Investigational site, Surrey

Galderma Investigational Site, Waterloo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Galderma R&D

INDUSTRY

NCT01880320 - Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris | Biotech Hunter | Biotech Hunter